Patrick Dempsey Teams up With Breakaway from Cancer(R)

AmgenPatrick Dempsey is speaking out to help connect cancer patients to the free resources available to them via Amgen's Breakaway from Cancer(R) initiative.

"Cancer entered my life in 1997 when my mother was first diagnosed with ovarian cancer," explained Dempsey. "I remember the feelings well - it was overwhelming. My family was trying to come to terms with the fear and shock of the diagnosis, while also working to sort through vast amounts of information to try and make the 'right' decisions for my mother's care."

Dempsey first teamed up with Breakaway from Cancer in 2007 to help bring the issue of better supporting patients to the forefront. In 2008, he founded The Patrick Dempsey Center for Cancer Hope & Healing at the Central Maine Medical Center -- the same hospital where Patrick was born and his mother received her cancer treatment.

Patrick Dempsey has now filmed a public service announcement (PSA) to raise awareness of the wide range of resources available to help people fight cancer. In the video, Dempsey talks about the challenges of choosing the right path and making the right choices - and urges people to take advantage of the free resources available via Breakaway from Cancer.

Breakaway from Cancer represents a collaboration between Amgen and four nonprofit partner organizations to connect individuals with support services ranging from cancer prevention, assistance during treatment, and embracing survivorship. The Breakaway from Cancer website provides a 'one-stop shop' of essential resources, including a navigator tool to help maneuver through the complicated maze of online information that currently exists. The tool conducts a targeted search based on user-entered criteria from more than 100 hand-selected credible cancer websites to offer patients the information they need.

Wherever you may be in your cancer journey, Breakaway from Cancer is here to help you find your way," Dempsey explains. "Whether you're newly diagnosed or have finished your treatment, breakawayfromcancer.com has resources you can use - all in one place."

To watch the PSA, visit http://www.breakawayfromcancer.com.

About Breakaway from Cancer(R)
Founded in 2005 by Amgen, Breakaway from Cancer(R) is a national initiative to increase awareness of important resources available to people affected by cancer - from prevention through survivorship. Through Breakaway from Cancer, Amgen has joined forces with four nonprofit partner organizations: Prevent Cancer Foundation, Cancer Support Community (formerly known as The Wellness Community), Patient Advocate Foundation, and National Coalition for Cancer Survivorship. These organizations offer a broad range of support services complementing those provided by a patient's team of healthcare professionals.

About Amgen
Amgen discovers, develops, manufactures, and delivers innovative human therapeutics. A biotechnology pioneer since 1980, Amgen was one of the first companies to realize the new science's promise by bringing safe, effective medicines from lab to manufacturing plant to patient. Amgen therapeutics have changed the practice of medicine, helping millions of people around the world in the fight against cancer, kidney disease, rheumatoid arthritis, bone disease, and other serious illnesses. With a deep and broad pipeline of potential new medicines, Amgen remains committed to advancing science to dramatically improve people's lives.

Most Popular Now

Fasenra (benralizumab) receives US FDA approval fo…

AstraZeneca and its global biologics research and development arm, MedImmune, announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab)...

Alzheimer's disease might be a 'whole body' proble…

Alzheimer's disease, the leading cause of dementia, has long been assumed to originate in the brain. But research from the University of British Columbia and Chinese scie...

Cancer cells destroyed with dinosaur extinction me…

Cancer cells can be targeted and destroyed with the metal from the asteroid that caused the extinction of the dinosaurs, according to new research by an international col...

Novartis confirms leadership in multiple sclerosis…

Novartis today announced it will present 54 scientific abstracts from across its multiple sclerosis (MS) research portfolio at the 7th Joint European and Americas Committ...

Amgen and Novartis announce expanded collaboration…

Amgen (NASDAQ:AMGN) and Novartis announced an expanded collaboration with the Banner Alzheimer's Institute (BAI) to initiate a new trial - the Alzheimer's Prevention Init...

Transplanted hematopoietic stem cells reverse dama…

Researchers at University of California San Diego School of Medicine report that a single infusion of wildtype hematopoietic stem and progenitor cells (HSPCs) into a mous...

Novartis announces the planned acquisition of Adva…

Novartis announced today, that it has entered a memorandum of understanding with Advanced Accelerator Applications (AAA) under which Novartis intends to commence a tender...

'Precision Medicine' may not always be so precise

Precision Medicine in oncology, where genetic testing is used to determine the best drugs to treat cancer patients, is not always so precise when applied to some of the w...

China's out of control 'silent killer' affects one…

More than one-third of adults in China have high blood pressure - often dubbed the "silent killer" for its lack of symptoms - but only about one in 20 have the condition ...

New tissue-engineered blood vessel replacements on…

Researchers at the University of Minnesota have created a new lab-grown blood vessel replacement that is composed completely of biological materials, but surprisingly doe...

New US study reveals key reasons why millions of p…

Few of the more than 90 million Americans(1) with obesity are seeking and receiving long-term obesity care, according to new data from the Awareness, Care and Treatment I...

Efficacy and safety maintained in patients who swi…

Boehringer Ingelheim today announced one-year data from VOLTAIRE®-RA, a pivotal Phase III clinical trial comparing Cyltezo® (adalimumab-adbm) and reference product Humira...

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]